Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV.
Sci Rep
; 13(1): 8189, 2023 05 20.
Article
em En
| MEDLINE
| ID: mdl-37210393
ABSTRACT
Severe fever with thrombocytopenia syndrome virus was first discovered in 2009 as the causative agent of severe fever with thrombocytopenia syndrome. Despite its potential threat to public health, no prophylactic vaccine is yet available. This study developed a heterologous prime-boost strategy comprising priming with recombinant replication-deficient human adenovirus type 5 (rAd5) expressing the surface glycoprotein, Gn, and boosting with Gn protein. This vaccination regimen induced balanced Th1/Th2 immune responses and resulted in potent humoral and T cell-mediated responses in mice. It elicited high neutralizing antibody titers in both mice and non-human primates. Transcriptome analysis revealed that rAd5 and Gn proteins induced adaptive and innate immune pathways, respectively. This study provides immunological and mechanistic insight into this heterologous regimen and paves the way for future strategies against emerging infectious diseases.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vacinas Virais
/
Adenovírus Humanos
/
Febre Grave com Síndrome de Trombocitopenia
Limite:
Animals
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article